Published in J Clin Oncol on March 21, 2016
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12
Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol (2016) 0.96
Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol (2017) 0.85
POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies. Gene (2016) 0.85
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov (2016) 0.84
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest (2017) 0.82
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? Front Oncol (2016) 0.80
Genomic landscape of high-grade meningiomas. NPJ Genom Med (2017) 0.78
Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol (2017) 0.77
Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clin Cancer Res (2016) 0.77
When Genome Maintenance Goes Badly Awry. Mol Cell (2016) 0.77
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology (2016) 0.75
The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis. Oncotarget (2016) 0.75
Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next? Cancer Discov (2016) 0.75
Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nat Commun (2017) 0.75
Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. Transl Lung Cancer Res (2016) 0.75
Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. Oncoimmunology (2017) 0.75
Immunotherapy: Exploiting mismatch repair in GBM. Nat Rev Clin Oncol (2016) 0.75
Actionable molecular biomarkers in primary brain tumors. Trends Cancer (2016) 0.75
Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncol (2016) 0.75
Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A (2016) 0.75
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. Onco Targets Ther (2017) 0.75
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. Oncotarget (2017) 0.75
In search of a target: PD-1 and PD-L1 profiling across glioma types. Neuro Oncol (2016) 0.75
Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Invest (2017) 0.75
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. Oncoimmunology (2017) 0.75
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell (2017) 0.75
Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. Per Med (2017) 0.75
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Curr Treat Options Oncol (2017) 0.75
CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology. ESMO Open (2017) 0.75
Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J Neurooncol (2017) 0.75
Novel vaccines for glioblastoma: clinical update and perspective. Immunotherapy (2016) 0.75
History and current state of immunotherapy in glioma and brain metastasis. Ther Adv Med Oncol (2017) 0.75
Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment. Neuro Oncol (2017) 0.75
SOX2 immunity and tissue resident memory in children and young adults with glioma. J Neurooncol (2017) 0.75